We have over 150 beds across our 3 inpatient clinical trial sites in the UK and EU, each with dedicated teams experienced in delivering clinical trials, from first-in-human through to Phase IIa studies.
We are the world leader in conducting human challenge studies in infectious disease and opened our flagship 50-bed quarantine facility in London in 2024. The inpatient clinical trial unit has state-of-the-art isolation infrastructure, as well as integrated laboratory, pharmacy, and catering facilities.
Our expertise also spans early phase studies (including complex pharmacokinetic and pharmacodynamic studies as well as studies in participants with renal and hepatic impairment), asthma and respiratory medicine, cardiometabolic medicine, dermatology, pain management, and the central nervous system.
Available beds
Sites in the UK and the EU
In 2024, we opened our state-of-the-art quarantine facility in Canary Wharf, London. As the world’s largest human challenge clinical trial unit, it contains 50 inpatient beds and a 10-bed outpatient unit on a single floor. hVIVO’s office headquarters and hLAB, our specialist virology and immunology laboratory, lie directly below, allowing for seamless operations between our clinical and laboratory teams. Our quarantine facility and hLAB are certified to work with pathogens up to biosafety level 3 (BSL3) and can work with multiple pathogens concurrently. Our flagship site could help accelerate the development of your vaccine or therapy.
50-bed inpatient unit
HEPA-filtered, negative pressure quarantine rooms
Self air handling units & power supply back up
On-site pharmacy for IMP storage & dispensation
Integrated virology & immunology laboratory facilities
Pneumatic tube connection for 30 sec samples transfer
Nurse to bedroom 2-way call & intercom system
High grade hospital furniture & highest comfort mattress
43” Smart TV & PlayStation5 in every room
Freshly prepared food daily
10-bed outpatient unit
Our Phase I/II clinical trial site in Mannheim, Germany hosts 94 inpatient beds, including 58 beds dedicated to long-term stays, split across 3 wards. The site also offers a large outpatient facility making it adaptable to various clinical trial designs.
Our Mannheim site excels in first-in-human, QTc and lung function studies, narcotics/opioids research, drug-drug and food-drug interactions, and bioequivalence and bioavailability studies. The clinic is also recognized for its expertise in cardiometabolic research, focusing on obesity, diabetes, metabolic disorders, and cardiovascular diseases.
94 inpatient beds inc 58 high-care beds for long-term stays
3 separate wards
Continuous monitoring & advanced telemetry capabilities
800 m2 outpatient facility with separate entrance
Private consultation & examination rooms
Laminar flow hood
Minimally invasive operating theatre
IMP processing facilities within 500m of site
Our specialised site in Kiel, Germany is dedicated to pharmacokinetic and pharmacodynamic studies in participants with renal and hepatic impairment or elderly participants. Designed to accommodate the unique needs of these patient populations, the Kiel clinic provides specialised medical oversight, ensuring safety and precision in early-phase trials.
26 inpatient beds inc 20 high-care beds for long term stays
On-site nephrologist
Collaboration with 2 hepatology referral practices
Continuous monitoring & advanced telemetry capabilities
On-site pharmacy for IMP storage & dispensation
Private consultation/examination rooms
On-site laboratories for blood & urine processing
Set in a 300 m2 townhouse
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
